Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Psyence Group (PSYG) and Pure Extracts (PULL) sign JV Letter of Intent for the extraction of psilocybin from psychedelic mushrooms and development of psilocybin formulations
  • This will also include the development of advanced formulations containing psilocybin for the long-term treatment
  • The Psyence Group sets the global standard for natural psychedelics
  • Pure Extracts features an all-new, state-of-the-art processing facility
  • Pure Extracts Technologies Corp (PULL) is up 11.49 per cent and is trading at C$0.48 at 1.43 pm ET

Psyence Group (PSYG) and Pure Extracts Technologies (PULL) will jointly develop techniques for the extraction of psilocybin from psychedelic mushrooms.

This will include developing advanced formulations containing psilocybin for the long-term treatment of psychological trauma and its mental health consequences.

Psyence is one of the world’s first psychedelic mushroom companies operating a federally legal commercial cultivation and extraction facility in Southern Africa.

It has an experienced global team of doctors and scientists striving for breakthroughs in palliative care, neurology, neuroscience and drug development.

Pure Extracts is a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector with a state-of-the-art processing facility.

The companies plan to maximize the use of their combined infrastructure and networks in order to attain near-term milestones.

Pure Extracts has a strong Canadian network of psychedelic mushroom experts, from cultivation to research & development, including Dr. Alexander MacGregor and his team at the Toronto Institute of Pharmaceutical Technology (TIPT).

While Psyence’s network in South Africa, Lesotho and Jamaica have the expertise for the JV to rapidly develop natural psychedelics and novel drug delivery systems for patients throughout the world.

Additionally, the Psyence team is experienced in structuring and running clinical trials and a near term goal will be to participate in a Canadian based, human clinical trial.

Pure Extracts CEO, Ben Nikolaevsky, remarked,

“We are excited about working with the deeply qualified science team at Psyence, one of only a handful of companies in the world operating a vertically integrated, federally licensed, psychedelic mushroom facility.”

Dr. Justin Grant, Chief Scientific Officer of Psyence, commented,

“This partnership with Pure Extracts will facilitate the importation of our standardized psychedelic mushrooms into Canada, giving us the opportunity to further optimize extraction methods and produce advanced products needed for safe clinical research.”

The Psyence Group sets the global standard for natural psychedelics.

Pure Extracts features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia.

Pure Extracts Technologies Corp (PULL) is up 11.49 per cent and is trading at C$0.48 at 1.43 pm ET.

More From The Market Herald
Levitee Labs - CEO, Pouya Farmand.

" Levitee Labs (CSE:LVT) partners with Adracare for addiction and mental health support

Levitee Labs (LVT) has signed an agreement with Adracare to develop a platform for mental health services.

" Cardiol Therapeutics (TSX:CRDL) expands phase II/III trial of CardiolRx

Cardiol Therapeutics (CRDL) is expanding its LANCER trial to include several hospital centers in Brazil, Mexico, and Canada.

" XORTX Therapeutics (CSE:XRX) closes public offering

XORTX Therapeutics (XRX) announced the closing of a US$12M public offering.

" Marvel Biosciences (TSXV:MRVL) updates the status of its MB-204 manufacturing efforts

Marvel Biosciences Corp. (MRVL) reports a successful process development of the active pharmaceutical ingredient of its lead drug MB-204.